Sydney Lupkin
From this contributor
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Eight pharmaceutical companies more than doubled their lobbying spending in the first three months of 2017.
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Health companies gave generously to President Trump’s inauguration
Facing acute risks to their businesses from Washington policymakers, health companies spent more than $2 million to buy access to the incoming Trump administration via candlelight dinners, black-tie balls and other inauguration events.
Health companies gave generously to President Trump’s inauguration
Trump’s choice to run food and drug agency has pharma connections
Scott Gottlieb, nominated to lead the U.S. Food and Drug Administration has deep ties to industry, and has worn many other hats in his career.
Trump’s choice to run food and drug agency has pharma connections
Senators call for investigation into possible abuses of Orphan Drug Act
Building on weeks of mounting pressure to address high prescription drug prices, three influential U.S. senators have asked the government’s accountability arm to probe the orphan drug program for potential misuse.
Senators call for investigation into possible abuses of Orphan Drug Act
Former head of FDA concerned about faster drug approvals
Robert Califf, the just-departed commissioner of the U.S. Food and Drug Administration, offers his take on the Trump administration's plans to speed up drug approvals and dramatically reduce regulations at the agency.
Former head of FDA concerned about faster drug approvals
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.